DSIPAlso known as: Delta Sleep-Inducing Peptide, DSIP Peptide

Mechanism of Action

DSIP modulates central nervous system signaling pathways by influencing neuro-endocrine interactions. It is believed to promote slow-wave sleep (deep sleep phases) by regulating melatonin secretion and reducing stress hormone levels such as cortisol. It also exerts antioxidative effects and may modulate growth hormone release, impacting sleep quality and neuroprotection.

Reported Research Benefits

Investigated for improving sleep architecture especially deep sleep cycles; studied in chronic stress recovery and hormonal balance including cortisol and growth hormone (GH); researched for neuroprotective effects and potential applications in mood disorders such as depression and anxiety; evaluated in jetlag and circadian rhythm disruption studies.

Dosing Protocol & Reconstitution

DSIP is supplied in lyophilized powder form and dissolved in bacteriostatic water before subcutaneous injection using insulin syringes in experimental lab settings. Typical research doses vary and must be precisely calculated using appropriate peptide calculators. Storage post-dissolution is recommended at 2–8°C with a shelf life up to 60 days.

Research Notes

Preclinical studies show DSIP increases slow-wave sleep duration and improves biological rhythm alignment. It may reduce oxidative stress markers and modulate neuroendocrine hormones. Injection routes and dosages differ among studies but commonly employ subcutaneous administration. Research is ongoing regarding its efficacy in sleep disorders and stress-related pathology.

Research Summary

Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide originally isolated from cerebral venous blood that promotes slow-wave (delta) sleep. It also modulates stress responses by normalizing cortisol and LH secretion, and has shown analgesic and anti-oxidative properties in animal studies. Human trials have demonstrated improvements in sleep quality in insomnia and opiate withdrawal.

Side Effects & Safety

Generally well-tolerated in human studies. Mild drowsiness (desired effect), transient headache, and dizziness reported. May interact with opioid receptor systems. Limited long-term safety data.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: Gly-Leu-Val-Asp-Ser-Arg-Gly-Glu
Molecular Formula: C50H67N15O10
Molecular Weight: 1147.2 g/mol
CAS Number: 62568-57-4
IUPAC Name: Glycyl-L-leucyl-L-valyl-L-aspartyl-L-seryl-L-arginyl-glycyl-L-glutamic acid

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=DSIP+delta+sleep+inducing+peptide